CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-25
Target enrollment:
Participant gender:
Summary
This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Affiliated Hospital to Academy of Military Medical Sciences